Thermo Fisher opens biologics manufacturing site in Switzerland

  • Thermo Fisher Scientific (NYSE:TMO) has assumed operational responsibility for a new biologics manufacturing site in Lengnau, Switzerland as part of its strategic partnership with CSL Limited announced last year.
  • The Lengnau site will become part of TMO's global biologics manufacturing network, and approx. 200 employees will join. The site is a 1.5M square-foot facility that will leverage highly flexible bioproduction technologies, including both single-use and stainless steel with up to 12,500L bioreactor capacity.
  • "Through our partnership with CSL, this site further strengthens our unique customer value proposition to leverage our scale and depth of capabilities for pharma and biotech customers," said Michel Lagarde, executive vice president of Thermo Fisher Scientific .
  • Following completion of site construction in 2022, TMO will initially support manufacturing of CSL's next-generation recombinant factor IX product Idelvion for patients with hemophilia B. Over time, Thermo Fisher plans to expand the use of the site to include additional biopharma customers.

    Over the current book year the total revenue from the company in Waltham will be 36.05 billion USD (consensus estimates). This is hugely more than 2021's revenue of 32.22 billion USD.

    Historical revenues and results Thermo Fisher Scientific plus estimates 2021

    beurskoers

    The analysts expect for 2021 a net profit of 8.77 billion USD. The majority of the analysts expects for this year a profit per share of 22.17 USD. With this the price/earnings-ratio is 26.34.

    Per share the analysts anticipate on a dividend of 97 cents per share. Thus the dividend yield equals 0.17 percent. The average dividend yield of the health care companies equals a low 1.27 percent.

    Based on the current number of outstanding shares Thermo Fisher Scientific 's market capitalization is 232.83 billion USD. 26

    On Friday, the stock closed at 583.92 USD.

    Historical stock prices Thermo Fisher Scientific

    stock prices thermofisherscientific

    ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
    news@valuespectrum.com

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.

    • Other stock news
    Thermo Fisher bid to acquire PPD comes under regulatory scrutiny in U.K.
    Thermo Fisher to spend $17 billion on PPD acquisition
    Analysts expect over 2020 rising revenue Thermo Fisher Scientific
    Analysts expect over 2020 rising revenue Thermo Fisher Scientific
    Sector news
    Analysts foresee more revenue Basic-Fit
    Analysts expect over 2024 revenue expansion Basic-Fit
    Analysts expect over 2024 shrinking sales Delivery Hero
    Analysts expect over 2023 revenue decrease Basic-Fit
    Analysts: less sales Stericycle
    Ibersol now in top highest dividend yields in Portugal
    Analysts foresee record year for Agilent Technologies
    National news
    Analysts: less sales 3M
    Analysts estimate for 2024 rising sales Amphenol
    Analysts count on revenue increase Travelers
    Analysts anticipate for 2024 on revenue increase Kinder Morgan, high dividend yield
    Currently quite high dividend Citigroup
    Analysts foresee more revenue Kinder Morgan, quite high dividend
    Analysts expect over 2024 revenue increase JP Morgan Chase
    Press news
    Test News
    Discover the Future: IoT-Based Asset Tracking and Monitoring Market Insights for 2029 – Get the Market Analysis!
    TOP RANKED ROSEN LAW FIRM Encourages Paladin Energy Ltd Investors to Inquire About Securities Class Action Investigation – PALAF
    ROSEN, A LEADING NATIONAL FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kaspi, Applied Therapeutics, Cassava, and MGPI and Encourages Investors to Contact the Firm
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge and Revance and Encourages Investors to Contact the Firm
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, Nextracker, and Transocean and Encourages Investors to Contact the Firm
    Logoanalist
    Returns European stocks
    Crypto currencies information
    About us Network Partners
    Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos Analist.nlLinksISIN
  • Glossary
    		• MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-xBats
    ©2025 ValueSpectrum. All Rights Reserved
    Developed and maintained by  Velainn logo